Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Intranasal administration of acetylcholinesterase inhibitors.

Costantino HR, Leonard AK, Brandt G, Johnson PH, Quay SC.

BMC Neurosci. 2008 Dec 10;9 Suppl 3:S6. doi: 10.1186/1471-2202-9-S3-S6. Review.

2.

In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.

Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Costantino HR.

Int J Pharm. 2007 Apr 20;335(1-2):138-46. Epub 2006 Nov 16.

PMID:
17174048
3.

High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses.

Flechtner JB, Cohane KP, Mehta S, Slusarewicz P, Leonard AK, Barber BH, Levey DL, Andjelic S.

J Immunol. 2006 Jul 15;177(2):1017-27.

4.

Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.

Chen SC, Eiting K, Cui K, Leonard AK, Morris D, Li CY, Farber K, Sileno AP, Houston ME Jr, Johnson PH, Quay SC, Costantino HR.

J Pharm Sci. 2006 Jun;95(6):1364-71.

PMID:
16625659
5.

Development of a novel high-concentration galantamine formulation suitable for intranasal delivery.

Leonard AK, Sileno AP, MacEvilly C, Foerder CA, Quay SC, Costantino HR.

J Pharm Sci. 2005 Aug;94(8):1736-46.

PMID:
15986464
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk